GURU.Markets stock price, segment price, and overall market index valuation
The company's share price UroGen Pharma Ltd.
UroGen Pharma is a biotechnology company specializing in the treatment of urological cancers. Its share price is dependent on sales of its lead drug, Jelmyto, and progress in developing new non-surgical treatments for urinary tract cancer.
Share prices of companies in the market segment - Cancer cure
UroGen Pharma (URGN) is a biotechnology company focused on the development and commercialization of innovative solutions for the treatment of urological cancers. We classify it in the "Cancer Treatment" segment. The chart below shows the overall dynamics of pharmaceutical companies fighting oncology.
Broad Market Index - GURU.Markets
UroGen Pharma is an Israeli biopharmaceutical company that has developed an innovative technology for the non-surgical treatment of urinary tract cancer. As a component of the GURU.Markets index, it represents the oncology sector. The chart below shows the US market. See how UroGen shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
URGN - Daily change in the company's share price UroGen Pharma Ltd.
Shares of UroGen Pharma, a urologic cancer treatment company, are highly volatile. Change_co measures market reaction to its drug's sales data and trial results. This metric is an important component of System.GURU.Markets' formulas that evaluate commercial success in biotech.
Daily change in the price of a set of shares in a market segment - Cancer cure
UroGen Pharma Ltd. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with URGN, which focuses on urologic cancer treatment, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
UroGen is a biopharmaceutical company specializing in urologic cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating UroGen shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization UroGen Pharma Ltd.
UroGen is a biopharmaceutical company specializing in the treatment of urological cancers. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Cancer cure
UroGen Pharma Ltd. is a commercial biopharmaceutical company focused on the treatment of urologic cancers. Its innovative drug delivery technology is its key advantage. The chart shows how its niche strategy and commercialization success influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
UroGen is a biopharmaceutical company whose stock performance is driven by the commercialization of its cancer treatments and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization UroGen Pharma Ltd.
The market capitalization of UroGen, a biopharmaceutical company, depends on the success of its drugs. The monthly fluctuations on the chart reflect sales data for its innovative bladder cancer gel, the commercial success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Cancer cure
UroGen Pharma develops and commercializes innovative solutions for the treatment of urological cancers using its unique slow-release drug technology. The chart below reflects overall investor sentiment in the cancer drug development sector, allowing one to assess UroGen's potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
UroGen Pharma Ltd. is an Israeli biotechnology company specializing in the treatment of urologic cancer. The company's success depends on the commercialization of its drugs and the results of new research. Share price performance is event-driven and completely independent of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization UroGen Pharma Ltd.
For UroGen Pharma, a company specializing in the treatment of urologic cancer, weekly price movements are extremely volatile. News about sales of its approved drug, trial results for new indications, and competitor actions can cause sharp and significant price fluctuations.
Weekly dynamics of market capitalization of the market segment - Cancer cure
UroGen Pharma and the entire urology-focused biotech sector are moving against a backdrop of scientific breakthroughs and regulatory decisions. These factors create general volatility for everyone. The chart will show how the company fares in this innovative yet risky field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like UroGen Pharma often live in their own world, isolated from broader market fluctuations. The fate of their stocks is determined by FDA news, not inflation reports. The chart will show how often their stock moves against the broader market tide.
Market capitalization of the company, segment and market as a whole
URGN - Market capitalization of the company UroGen Pharma Ltd.
UroGen Pharma's market capitalization is the financial valuation of a biotech company that has developed an innovative non-surgical treatment for upper urinary tract cancer. The chart reflects the commercial potential of its gel drug delivery technology. Its dynamics tell the story of how this new approach could change the standard of care in a niche oncology field.
URGN - Share of the company's market capitalization UroGen Pharma Ltd. within the market segment - Cancer cure
UroGen Pharma develops innovative drugs for the treatment of urological cancers using its slow-release gel technology. Its market share in the oncology sector reflects its leadership in this niche. The chart shows the demand for its non-surgical treatments in urology.
Market capitalization of the market segment - Cancer cure
UroGen Pharma develops innovative treatments for urological cancers. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect the search for less invasive and more effective therapies. UroGen's technology enables the delivery of chemotherapy directly to the tumor.
Market capitalization of all companies included in a broad market index - GURU.Markets
Urologic cancer treatment, as shown in the graph, requires innovative approaches. UroGen Pharma is developing a gel technology for delivering chemotherapy directly to the tumor. Its capitalization is a bet that this method could become an alternative to surgery.
Book value capitalization of the company, segment and market as a whole
URGN - Book value capitalization of the company UroGen Pharma Ltd.
UroGen's book value is the material basis for innovative treatment of urologic cancer. The chart reflects the value of its RTGel reversible hydrogel technology, which enables chemotherapy delivery directly to the tumor. These assets are transforming the approach to treatment.
URGN - Share of the company's book capitalization UroGen Pharma Ltd. within the market segment - Cancer cure
UroGen Pharma, a biopharmaceutical company, specializes in the treatment of urological cancers. Its share of the sector's assets is determined by its manufacturing capacity for its unique gel drug delivery technology. This physical base is key to the commercialization of its products.
Market segment balance sheet capitalization - Cancer cure
UroGen Pharma develops drugs for the treatment of urologic cancer. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. As a commercial company, UroGen invests not only in R&D but also in the infrastructure for marketing its drugs.
Book value of all companies included in the broad market index - GURU.Markets
UroGen Pharma Ltd. is a pharmaceutical company developing new treatments for urologic cancers. Its value lies in its RTGel™ reversible gel technology, which delivers drugs directly to tumors, and its commercial infrastructure.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - UroGen Pharma Ltd.
UroGen Pharma is a pharmaceutical company. Its valuation reflects its commercial product and its unique drug delivery technology, which can be applied to the treatment of other urological diseases.
Market to book capitalization ratio in a market segment - Cancer cure
UroGen Pharma develops innovative drugs for the treatment of urological cancers. Its key asset is its slow-release technology. The chart shows how the market evaluates the commercial potential of its approved drugs and developments compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
UroGen Pharma is a biopharmaceutical company specializing in the development of new treatments for urologic cancers. Compared to the average market valuations shown in this chart, its valuation is based on the commercial success of its first product and the potential of its unique drug delivery technology.
Debts of the company, segment and market as a whole
URGN - Company debts UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company specializing in the development of new treatments for urological cancers. Bringing innovative drugs to market requires significant investment in clinical trials and manufacturing. This chart shows how the company raises funds to commercialize its products and fund further research.
Market segment debts - Cancer cure
UroGen Pharma is a biopharmaceutical company specializing in the treatment of urological cancers. The company is in the commercialization phase of its first product, which requires marketing expenses. This chart shows how the company is funding this transition from R&D to sales.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company specializing in the treatment of urological cancers. This chart shows its financial structure. For a company with an approved product, moderate debt may be normal for funding marketing and further research. However, its growth requires investor attention.
Market segment debt to market segment book capitalization - Cancer cure
UroGen Pharma specializes in developing innovative treatments for urological cancers. Biopharmaceutical developments in oncology require significant capital for clinical trials. This chart shows the overall debt burden in the industry, allowing us to assess how UroGen finances its journey from the lab to potential market launch.
Debt to book value of all companies in the market
UroGen Pharma Ltd. is a pharmaceutical company developing innovative treatments for urological cancers. While commercializing its first product, the company incurs significant marketing expenses. This chart shows how readily available debt is to finance this important milestone, compared to shareholder dilution.
P/E of the company, segment and market as a whole
P/E - UroGen Pharma Ltd.
This chart shows the valuation of UroGen Pharma, a company specializing in the treatment of urological cancers. The company's P/E (when it becomes positive) will depend on the success of its innovative drug delivery methods, which avoid more invasive procedures. This is a bet on a new standard of treatment.
P/E of the market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company specializing in the development and commercialization of innovative solutions for the treatment of urological cancers. This chart shows the average valuation for the sector, providing investors with context for assessing UroGen's scientific potential and commercial prospects.
P/E of the market as a whole
UroGen Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of urologic cancers. Its valuation depends on the commercial success of its lead drug, Jelmyto, and the development of new programs. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of the urologic oncology market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company specializing in the development of innovative treatments for urological cancers. Its key product offers a non-surgical alternative. This chart shows investor expectations for the future commercial success of this drug and its potential to change the standard of care in its field.
%20P%2FE%20UroGen%20Pharma%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-UroGen-Pharma-Ltd.&v=1772641411797 "Chart of the company's future (projected) P/E UroGen Pharma Ltd.")
Future (projected) P/E of the market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company developing innovative solutions for the treatment of urological cancers, such as bladder cancer. Their main product uses gel technology to deliver chemotherapy. The chart reflects average profitability expectations for the biotech sector. URGN's position relative to this benchmark reflects the market's appreciation of their unique treatment approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772641411807 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
UroGen Pharma Ltd. is an Israeli biopharmaceutical company developing treatments for urologic cancers. Its valuation depends on the success of its drugs and their market acceptance. This overall market sentiment graph influences the availability of capital to fund the company's commercialization and further research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641411811 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit UroGen Pharma Ltd.
UroGen Pharma is a biotechnology company specializing in the development of new treatments for urological cancers. Its financial performance, as shown in the graph, depends on sales of its first approved drug, Jelmyto. Successful commercialization and expansion of the drug's use are key to long-term profitability.
Profit of companies in the market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company developing innovative solutions for the treatment of urological diseases, particularly bladder cancer. Its approach is based on sustained drug delivery. This chart represents the overall revenue in the cancer treatment sector. It demonstrates the industry's overall success in commercializing new therapeutic approaches, particularly in uro-oncology.
Overall market profit
UroGen Pharma develops innovative treatments for urological cancers. Like many biotech companies, it depends on the success of clinical trials and regulatory approvals. The overall market situation, as shown in this chart, directly impacts its ability to attract the capital needed to bring life-saving drugs to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company UroGen Pharma Ltd.
UroGen Pharma specializes in developing drugs for the treatment of urological cancers using its gel technology for sustained drug delivery. This graph reflects analysts' expectations for the commercial success of its lead product and the potential of its R&D pipeline in this niche but important area of oncology.
%20profit%20of%20the%20company%20UroGen%20Pharma%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-UroGen-Pharma-Ltd.&v=1772641411935 "Graph of future (projected) profit of the company UroGen Pharma Ltd.")
Future (predicted) profit of companies in the market segment - Cancer cure
UroGen Pharma specializes in developing innovative treatments for urological cancers, using its unique technology to deliver chemotherapy directly to the tumor. The company's success depends on the acceptance of its products by doctors. This chart shows forecasts for the pharmaceutical sector, helping to assess UroGen's potential to change the standard of care in its niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772641411955 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
UroGen Pharma is a biopharmaceutical company specializing in the treatment of urologic cancers. Its revenue and prospects depend on the success of its drugs and regulatory approvals. Overall economic conditions, as assessed by this chart, have minimal impact on its operations.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641411979 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - UroGen Pharma Ltd.
UroGen Pharma is a biotechnology company focused on treating urological cancers using innovative drug delivery methods. This chart reflects market perceptions of its unique technology and the commercial potential of its approved product. The trend reflects expectations for sales growth and the success of future developments.
P/S market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company specializing in the development of innovative treatments for urologic cancers. Revenue is generated from sales of its flagship drug. This pharmaceutical sector chart helps assess how the market perceives UroGen's unique drug delivery technology and its commercial potential in oncology.
P/S of the market as a whole
UroGen Pharma is a biotech company focused on developing innovative treatments for urological cancers, such as bladder cancer. Its technology enables chemotherapy delivery directly to the tumor. This market revenue valuation chart helps understand how investors view the company's potential to change the standard of care in its niche.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company specializing in the development of innovative treatments for urological cancers, such as bladder cancer. This chart shows how investors view the future sales of its drugs. It reflects their expectations for the commercial success of existing products and the potential of the company's new developments.
%20P%2FS%20UroGen%20Pharma%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-UroGen-Pharma-Ltd.&v=1772641412051 "The graph of the company's future (projected) P/S UroGen Pharma Ltd.")
Future (projected) P/S of the market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company that developed Jelmyto, the first non-surgical treatment for urothelial cancer of the upper urinary tract. The company's valuation reflects investors' expectations regarding the commercial success of this drug and the potential of its gel drug delivery technology for the treatment of other urological diseases.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772641412089 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
UroGen Pharma develops innovative treatments for urological cancers. The company targets niche but serious diseases. Given the overall revenue growth picture illustrated by the chart, UroGen exemplifies a targeted approach in biotechnology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641412112 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company focused on urologic oncology. This chart shows revenue from sales of its flagship product, Jelmyto, an innovative treatment for upper urinary tract cancer. Growth depends on the drug's acceptance by the urologic community.
Sales of companies in the market segment - Cancer cure
UroGen Pharma (URGN) is a biotech company focused on developing innovative treatments for urological cancers, such as bladder cancer. Its technology enables chemotherapy delivery directly to the tumor. This figure reflects revenue in the oncology sector, where UroGen's approach has the potential to change the standard of care, preserving organs and improving quality of life.
Overall market sales
UroGen Pharma is a biotechnology company specializing in the development of new treatments for urologic cancers. Demand for its products is driven by medical needs, but the economic environment is important for market access. This graph, reflecting the state of the economy, affects the healthcare system's ability to pay for innovative and expensive treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company UroGen Pharma Ltd.
UroGen Pharma is a biotechnology company specializing in the development of innovative solutions for the treatment of urological cancers. Its lead product is designed to treat upper urinary tract cancer. This chart reflects analyst sales forecasts, which assess the commercial success of its unique drug delivery technology and demand from urologists.
%20sales%20of%20the%20company%20UroGen%20Pharma%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-UroGen-Pharma-Ltd.&v=1772641412176 "Schedule of future (projected) sales of the company UroGen Pharma Ltd.")
Future (projected) sales of companies in the market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company specializing in the development of innovative solutions for the treatment of urological cancers. This forecast chart details the expected sales of their lead product, Jelmyto. This allows analysts to assess the market potential of this drug and the prospects for other developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772641412195 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
UroGen Pharma is a biopharmaceutical company specializing in the development of innovative treatments for urologic cancers. The company's success depends on the commercialization of its products. This schedule, reflecting the state of the healthcare system, influences the willingness of hospitals and physicians to implement new, more expensive, but potentially more effective treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641412321 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company developing innovative solutions for the treatment of urological cancers. Its key product, Jelmyto, offers a non-surgical treatment option. The company's profitability depends on the successful commercialization of this drug. The chart shows how the company translates its unique developments into financial returns for shareholders.
Market segment marginality - Cancer cure
UroGen Pharma is a biopharmaceutical company specializing in the development of new treatments for urologic cancers. Its key product, Jelmyto, is designed to treat urothelial carcinoma. This chart shows the company's commercial profitability. Success depends on successful marketing and adoption of the drug by physicians.
Market marginality as a whole
UroGen Pharma develops innovative treatments for urological cancers. Its success depends on regulatory approval and acceptance by the medical community. This overall profitability chart reflects the overall health of the healthcare system. Financially healthy hospitals and insurers are more willing to cover the costs of new, more effective treatments.
Employees in the company, segment and market as a whole
Number of employees in the company UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company specializing in the treatment of urological cancers. As its products are brought to market, its team is expanding. This chart shows how the company is hiring sales and marketing specialists to promote its innovative treatments to urologists.
Share of the company's employees UroGen Pharma Ltd. within the market segment - Cancer cure
UroGen Pharma is a pharmaceutical company specializing in the treatment of urological cancers. It has already launched an innovative product. This chart reflects its status as a commercial company: the size of its staff indicates the presence of not only an R&D team but also a fully-fledged commercial infrastructure for promoting its specialized drugs.
Number of employees in the market segment - Cancer cure
UroGen Pharma develops innovative treatments for urological cancers. This chart, showing employment in the oncology sector, illustrates the scale and complexity of the fight against cancer. For UroGen, which focuses on non-surgical treatments, growth in this area means both increased awareness of new therapies and competition for the attention of urologists and oncologists.
Number of employees in the market as a whole
UroGen Pharma is a biopharmaceutical company specializing in uro-oncology. Its hiring of specialists in research, clinical trials, and sales is driven by the progress and approval of its new cancer treatments. It operates in a demand-driven market that is a vital part of the larger economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company UroGen Pharma Ltd. (URGN)
UroGen Pharma is a biopharmaceutical company that has developed an innovative non-surgical treatment for upper urinary tract cancer. The business is focused on a single breakthrough product. This metric reflects the enormous market value placed on the potential of this single product, developed by a small but effective team.
%20of%20the%20company%20UroGen%20Pharma%20Ltd.%20(URGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-UroGen-Pharma-Ltd.-URGN&v=1772641412500 "Chart of market capitalization per employee (in thousands of dollars) of the company UroGen Pharma Ltd. (URGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
UroGen Pharma specializes in developing drugs for the treatment of urological cancers. In this niche pharmaceutical field, value is determined by the potential of one or two key products. This chart shows the market premium placed on the company's innovations, based on its focused scientific team.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772641412522 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
UroGen Pharma is a biopharmaceutical company specializing in the development of new treatments for urologic cancers. The chart shows the company's valuation with an approved product. The high cost per employee reflects the potential revenue from sales of its innovative gel, which is transforming the treatment of a certain type of bladder cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641412538 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company UroGen Pharma Ltd. (URGN)
UroGen Pharma is a biopharmaceutical company specializing in the treatment of urologic cancer. They already have an approved product (Jelmyto). This chart shows how effectively their small commercial and medical teams are promoting this highly specialized, expensive drug among urologists and oncologists.
%20Chart%20UroGen%20Pharma%20Ltd.%20(URGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-UroGen-Pharma-Ltd.-URGN&v=1772641412547 "Company Profit Per Employee (in thousands of dollars) Chart UroGen Pharma Ltd. (URGN)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
UroGen Pharma is a biopharmaceutical company that developed Jelmyto, a non-surgical treatment for upper urinary tract cancer. The company is in the commercialization phase. This metric reflects how successfully their small sales team is promoting this innovative drug to urologists.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772641412551 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
UroGen Pharma is a biopharmaceutical company focused on the treatment of urological cancers. Their key product, Jelmyto, is a non-surgical treatment for upper urinary tract cancer. This chart shows how a biotech with an approved niche product generates profits. Employee efficiency depends on the high price of the drug and the efforts of a small sales team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641412554 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee UroGen Pharma Ltd. (URGN)
UroGen Pharma is a biopharmaceutical company focused on the treatment of urologic cancers. Its revenue per employee is generated by its first approved product, Jelmyto. The chart shows how the company is building on its commercial success by promoting this innovative non-surgical treatment method among urologists and oncologists for the treatment of this rare cancer.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-UroGen-Pharma-Ltd.-URGN&v=1772641412564 "Sales chart per company employee UroGen Pharma Ltd. (URGN)")
Sales per employee in the market segment - Cancer cure
UroGen Pharma (URGN) is a biopharmaceutical company specializing in the treatment of urological cancers, known for its drug Jelmyto. This chart shows the average revenue per employee in the segment. It helps assess how effectively UroGen generates sales for its innovative drug using its team.
Sales per employee for the market as a whole
UroGen Pharma (URGN) is a biopharmaceutical company focused on the treatment of urological cancers. They already have an approved product (Jelmyto) for the treatment of upper urinary tract cancer. This metric demonstrates commercial success and shows how much revenue their team (manufacturing and sales) generates from this highly specialized drug.
Short shares by company, segment and market as a whole
Shares shorted by company UroGen Pharma Ltd. (URGN)
UroGen Pharma (URGN) is a biotech company specializing in the treatment of urological cancers (such as bladder cancer) using its extended-release drug delivery technology. This chart shows "short" interest. The increase in the indicator may reflect investor doubts about the commercial success of its first drug, Jelmyto, or concerns about the complexity of clinical trials for new candidates. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-UroGen-Pharma-Ltd.-URGN&v=1772641412591 "Short Shares Chart for the Company UroGen Pharma Ltd. (URGN)")
Shares shorted by market segment - Cancer cure
UroGen is a biotech company that developed Jelmyto, a gel for the non-surgical treatment of upper urinary tract cancer. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward biotechs with a single product in a niche market.
Shares shorted by the overall market
UroGen Pharma (URGN) is a biotech company focused on treating urological cancers (such as bladder cancer) using innovative drug delivery systems. This chart highlights concerns about the commercial success of their drugs. Bears may not believe their treatments will be widely adopted by doctors, or their market potential is too small to justify a high valuation.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator UroGen Pharma Ltd. (URGN)
UroGen Pharma is a biotech company specializing in the treatment of urological cancers using its unique drug delivery technology. This chart measures how investors perceive the commercial success of their drug, Jelmyto. It shows when the stock is overbought due to sales growth expectations or oversold due to disappointment.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-UroGen-Pharma-Ltd.-URGN&v=1772641412633 "RSI 14 indicator chart for the company's stock UroGen Pharma Ltd. (URGN)")
RSI 14 Market Segment - Cancer cure
UroGen Pharma is a biopharmaceutical company specializing in the treatment of urological cancers. Their key product, Jelmyto, uses their RTGel technology to deliver chemotherapy for upper urinary tract cancer. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
UroGen Pharma (URGN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast URGN (UroGen Pharma Ltd.)
UroGen Pharma (URGN) is a biopharmaceutical company specializing in the treatment of urological cancers using its unique drug delivery technology. This chart shows the average target price. It reflects analysts' opinions on the commercial success of its drug Jelmyto and the potential of its other developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-URGN-UroGen-Pharma-Ltd.&v=1772641412659 "A chart showing analyst consensus forecasts for the expected stock price. URGN (UroGen Pharma Ltd.)")
The difference between the consensus estimate and the actual stock price URGN (UroGen Pharma Ltd.)
UroGen Pharma is a biotech company that has developed an innovative chemotherapy delivery platform (RTGel) for the treatment of urinary tract cancer (urothelial carcinoma). This chart shows the gap between the market's current valuation of URGN and analysts' expectations. This reflects their view of Jelmyto's commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-URGN-UroGen-Pharma-Ltd.&v=1772641412680 "A chart showing the difference between the consensus forecast and the actual stock price. URGN (UroGen Pharma Ltd.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
UroGen Pharma is a biotech company focused on urologic oncology. Its flagship drug, Jelmyto, is the first non-surgical therapy for upper urinary tract cancer. This chart shows analysts' overall expectations for the entire cancer treatment sector, reflecting whether experts believe there is demand for alternatives to surgery.
Analysts' consensus forecast for the overall market share price
UroGen Pharma is an Israeli biotech company focused on the treatment of urinary tract cancer (urologic oncology). Their technology delivers chemotherapy in a gel (Jelmyto). This chart shows overall market sentiment. For UroGen, which is commercializing a niche drug, it's important to understand how these expectations (hospital budgets) impact the adoption of their innovative therapy. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index UroGen Pharma Ltd.
UroGen (URGN) is a biopharmaceutical company focused on the treatment of urologic cancer (bladder cancer). Their signature feature is their RTGel platform, which delivers chemotherapy as a gel rather than systemically. This chart is their platform indicator. It measures the commercial success of their first drug (Jelmyto) and market confidence in the potential of their gel to treat other cancers.
AKIMA Market Segment Index - Cancer cure
UroGen (URGN) is a biotech focused on urology; the Israeli company has developed a unique technology (RTGel)—a gel that delivers chemotherapy (Jelmyto) directly to the kidney for cancer treatment. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this unique delivery technology (URGN) differentiate it from the average pharma company?
The AKIM Index for the overall market
UroGen Pharma is a biopharmaceutical company that has developed a hydrogel (Jelmyto) for the non-surgical treatment of urothelial cancer. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this niche oncology business stacks up against the backdrop of overall economic trends impacting the healthcare sector.
